2026-05-04T16:56:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/260282025-12-18T13:01:02Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16938col_20.500.12105_16963col_20.500.12105_16969col_20.500.12105_16976col_20.500.12105_16987

00925njm 22002777a 4500 dc García-Pérez, Javier author Borobia, Alberto M author Perez-Olmeda, Mayte author Portolés, Antonio author Castaño, Luis author Campins-Artí, Magdalena author Bertrán, María Jesús author Bermejo, Mercedes author Arribas, José Ramón author López, Andrea author Ascaso-Del-Rio, Ana author Arana-Arri, Eunate author Fuentes Camps, Inmaculada author Vilella, Anna author Cascajero Díaz, Almudena author García-Morales, María Teresa author Castillo de la Osa, María author Pérez Ingidua, Carla author Lora, David author Jiménez Santana, Paloma author Pino-Rosa, Silvia del author Gómez de la Cámara, Agustín author de la Torre-Tarazona, Humberto Erick author Calonge, Esther author Cruces Fernández, Raquel author Belda-Iniesta, Cristobal author Alcamí, José author Frías, Jesús author Carcas, Antonio J author Díez-Fuertes, Francisco author CombiVacS Study Group author 2024-09-20 CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739). García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F; CombiVacS Study Group. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants. iScience. 2024 Aug 14;27(9):110728. 10.1016/j.isci.2024.110728 2589-0042 iScience 39286494 https://hdl.handle.net/20.500.12105/26028 Immune response Immunology Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants